Medical Device Contract Manufacturing Market Insights: How Automation and AI Are Changing Production
The Medical Device Contract Manufacturing Market was estimated at around USD 82.08 billion in 2025 and USD 92.24 billion in 2026, and it is projected to reach USD 237.11 billion by 2034. That implies a CAGR of 12.51% from 2026 to 2034. Growth is being driven mainly by the rising burden of chronic disease and a growing aging population across the world. Medical device contract manufacturing means handing the design, development and production of a device to a specialized third party, usually a contract development and manufacturing organization (CDMO). These partners support original equipment manufacturers (OEMs) across the full product life cycle, from design and prototyping to assembly, sterilization and packaging.
Why OEMs Are Outsourcing
Rising product complexity and tougher regulatory requirements are making in-house production harder to justify. Building and maintaining compliant facilities is expensive, and OEMs are under pressure to cut costs and reach the market faster. Working with a CDMO lowers capital expenditure, adds manufacturing flexibility and gives access to specialized engineering skills. Instead of managing several vendors, OEMs can rely on a partner that covers the value chain, including raw material procurement, precision engineering, sterilization and final packaging.
Demographics and Disease Burden
Chronic conditions such as cardiovascular disease, diabetes, cancer and respiratory illness are creating steady demand for advanced devices. The World Health Organization projects that these diseases could account for 86% of the 90 million annual deaths by 2048 if current trends continue. An aging population adds to the pressure. The WHO expects one in six people worldwide to be over 60 by 2030, and the over-80 population is forecast to rise from 141 million in 2019 to 426 million by 2050. Implants, diagnostic tools, monitoring equipment and home healthcare devices will all be needed in greater volumes, and OEMs are leaning on CDMOs to keep up.
Regulation Cuts Both Ways
Strict approval processes remain a major restraint. Regulatory requirements differ by region, which complicates documentation, validation and certification, and delays can postpone product launches. At the same time, the compliance burden pushes companies toward experienced partners. FDA expectations, including the Quality Management System Regulation, and the EU’s MDR and IVDR frameworks demand extensive documentation and clinical validation. ISO 13485 compliance is also essential for international market access. CDMOs that invest in regulatory expertise and quality control gain a clear advantage in this environment.
Technology Is Raising the Standard
Automation, robotics and AI are improving precision and reducing human error in production. Smart manufacturing systems allow real-time tracking and predictive maintenance, which lowers costs and supports scalability. In February 2026, Made Scientific signed an agreement with Streamline Bio to apply AI and robotics to cell therapy manufacturing, showing how widely these tools are spreading.
Additive manufacturing and 3D printing allow faster prototyping and custom designs for intricate devices while reducing material waste. They suit low-volume, high-precision work. IoT and data analytics improve visibility across design, manufacturing and packaging, and CDMOs with connected systems tend to see higher efficiency and better customer retention.
Explore The Complete Comprehensive Report Here : https://www.polarismarketresearch.com/industry-analysis/medical-device-contract-manufacturing-market
Segment Highlights
By service type, the broader services category led in 2025 with approximately 38.60% of the market as OEMs outsourced more design, testing and compliance work. Design and development is expected to grow fastest because devices are becoming more complex and companies want quicker commercialization.
By device type, surgical devices led with around 35.45%, supported by rising surgical volumes and demand for precision instruments. In December 2025, Quvara Medical became a CDMO by acquiring a UK factory from Becton Dickinson for mass production of drug delivery devices. Wearable medical devices are projected to grow fastest, as remote monitoring and connected healthcare need compact, sensor-based products and flexible production.
By application, diagnostics and in vitro diagnostics held about 33.80% of the market, driven by early disease detection and high test volumes. Implantable devices are expected to record the highest growth as long-term therapies and implant innovation increase reliance on specialist manufacturers.
Regional Outlook
North America led in 2025 with approximately 40.75% of the market, backed by advanced healthcare infrastructure, a strong OEM presence and high outsourcing adoption. In February 2026, CDMO company MGS opened a 300,000 square foot facility for drug delivery devices to serve rising demand for combination products.
Asia Pacific is expanding quickly on cost efficiency and growing capability. Quasar Medical built a new site in Thailand in June 2025 to expand micro-assembly and device manufacturing, while China benefits from large-scale production and government support and India from skilled labor and rising investment.
Europe is growing at a CAGR of about 11.90%, driven by regulatory support and precision manufacturing demand, with Germany, France and the UK as the main outsourcing hubs.
Competitive Landscape
Competition is moderately fragmented, with global CDMOs competing against regional specialists on regulatory compliance, manufacturing precision and cost. Key participants include Flex, Jabil, Plexus, Sanmina, Integer Holdings, TE Connectivity, Gerresheimer, West Pharmaceutical Services, Celestica, Freudenberg Medical, Phillips-Medisize and Nortech Systems. Capacity expansions, mergers and acquisitions, and long-term OEM partnerships are common strategies as these firms build end-to-end capabilities.
Conclusion
Medical Device Contract Manufacturing Market growth through 2034 will be shaped by how well CDMOs combine regulatory expertise, advanced manufacturing technology and scalable capacity. Chronic disease, aging populations and the rise of wearables and implantables will keep demand strong, while approval delays and compliance complexity will reward providers with proven quality systems. OEMs that choose partners offering integrated services from design to sterilization can cut costs, reduce risk and bring innovative devices to patients sooner.
More Trending Latest Reports By Polaris Market Research:
Induced Pluripotent Stem Cell (Ipsc) Market
Balanoposthitis Treatment Market
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- الألعاب
- Gardening
- Health
- الرئيسية
- Literature
- Music
- Networking
- أخرى
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness